What GLP-1 Does Embody Use? The 2026 Plan-by-Plan Answer

Published: June 18, 2026 · Last reviewed: June 18, 2026

By The RX Index Editorial Team · Last verified: June 2026

What GLP-1 does Embody use? The short answer is right above. Here's the part the ads skip. These are compounded medicines, not the brand-name drugs you've seen on TV. The price can more than triple after your first month. And the rules around compounded GLP-1s changed in a big way across 2025 and 2026. We read Embody's own pages and the FDA's guidance line by line — and opened about a dozen browser tabs so you don't have to — so you can see exactly what you'd be getting.

Independent guidance for choosing your GLP-1 path. The RX Index is the independent GLP-1 decision resource that scores telehealth providers on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

Best for you if…

• You're checking out Embody specifically and want a cash-pay program (you pay directly, no insurance).
• You're open to a compounded semaglutide or tirzepatide treatment path if a clinician says it's appropriate.
• You want a choice between a weekly shot and a needle-free daily gum.
• You're willing to confirm the ongoing price — not just the intro price — before you commit.

Not for you if…

• You specifically want FDA-approved Wegovy, Zepbound, Ozempic, or Mounjaro.
• You need to use insurance or want help with prior authorization (your insurer's sign-off before they'll cover a drug).
• You're not comfortable taking a compounded medicine the FDA hasn't reviewed.

(If that last group is you, skip to “What if you want an FDA-approved brand instead?” — we'll point you somewhere better.)

The 30-second answer

What GLP-1 does Embody use?

Let's start with the words, because they trip people up. GLP-1 is short for glucagon-like peptide-1 — a natural gut hormone that helps control hunger and blood sugar. GIP is a second gut hormone (glucose-dependent insulinotropic polypeptide). Semaglutide works on the GLP-1 pathway. Tirzepatide works on two pathways at once — GLP-1 and GIP. These medicines act on your appetite and blood-sugar signals, so many people feel full sooner and eat less.

Here's why people get confused about Embody specifically. Its homepage often doesn't name the drug. It uses category labels like “GLP-1 Injections” and “GLP-1 / GIP Injections.” Those sound technical, but once you cross-check Embody's Terms and product pages, the labels line up with real medicines (Embody Terms, reviewed June 2026):

• “GLP-1 Injection” → semaglutide (the medicine sold in brand form as Ozempic and Wegovy)
• “GLP-1 / GIP Injection” → tirzepatide (the medicine sold in brand form as Mounjaro and Zepbound)
• “GLP-1 Gum” → a compounded semaglutide or tirzepatide gum (not the same as an FDA-approved oral tablet)

One thing to be clear about: Embody does not dispense those brand-name drugs. It dispenses compounded versions, which we explain in plain English in the next section. Naming what's inside Ozempic or Zepbound just helps you place the medicine — it does not mean Embody's compounded product is the same thing.

Embody's GLP-1 medications, reconciled (our verification matrix)

We built this by lining up Embody's homepage, its Terms & Conditions, its gum product pages, and its medication-safety page — because no single Embody page shows all of it at once.

Sources: Embody homepage, Terms & Conditions, gum product pages, and medication-safety page (joinem.co), reviewed June 2026; cross-checked against FDA compounding guidance. Pricing is promotional and changes — confirm your exact medicine, dose, and recurring price in checkout before paying.

So if you take one thing from this page: Embody uses compounded semaglutide and compounded tirzepatide, as a shot or a gum. Everything below helps you decide if that's right for you.

Is Embody's GLP-1 compounded or FDA-approved?

Here's the honest part, up front — because it matters more than anything else on this page.

Embody won't sell, ship, or hand you an FDA-approved brand-name GLP-1. If your goal is to get FDA-approved Wegovy or Zepbound, or to run it through insurance, then a brand-name path like Ro is the better fit, and we'll send you there. But because Embody skips the brand and the insurance maze, it can do the thing a lot of people actually want: get you onboarded online in minutes, ship to your door, and start at a low cash price — if a clinician decides treatment is appropriate for you.

That's the trade. Now let's make sure you understand both sides of it.

What “compounded” actually means

A compounded medicine is one a licensed pharmacy mixes to fill a specific patient's prescription. Embody says the medications prescribed through it are dispensed by U.S.-based 503A compounding pharmacies — state-licensed pharmacies that prepare medicines one prescription at a time (named after the part of federal law that allows it) (Embody, reviewed June 2026).

Compounding itself is legal and routine in pharmacy. But a compounded drug is not an FDA-approved finished product. In the FDA's own words, compounded drugs do not go through the agency's review for safety, effectiveness, or quality before they reach you (FDA, June 2026). That's not a claim they're unsafe — it's a statement about what was and wasn't checked. The FDA also says compounded drugs should only be used when an FDA-approved drug can't meet your medical needs.

What Embody itself says

To Embody's credit, its own pages say this clearly. Embody's medication-safety and product pages state that compounded semaglutide and tirzepatide are prepared by a licensed compounding pharmacy and have not been evaluated or approved by the FDA for safety, effectiveness, or quality (Embody, reviewed June 2026). We're not pulling that out of them — they put it in writing.

What the FDA says vs. what to ask Embody

Words we won't use (and you shouldn't trust on other sites)

A lot of review pages describe compounded GLP-1s as the “same active ingredient as Ozempic” or “clinically proven.” We don't write that, and the FDA's framework is the reason — in fact, the FDA lists “claims that a compounded drug is the same as an FDA-approved drug” as a telehealth red flag (FDA, June 2026). We'll say “compounded semaglutide” and “compounded tirzepatide,” and we'll keep them strictly separate from the FDA-approved brands. Want the full breakdown? See our guide to compounded semaglutide alternatives.

Compounded (Embody) vs. FDA-approved: what actually changes for you

Is compounded semaglutide and tirzepatide even legal in 2026?

This is the piece almost no other Embody page tells you, and it's exactly what a careful buyer needs in 2026.

During 2022–2024, these drugs were in shortage. When the FDA puts a drug on its shortage list, pharmacies are allowed to compound copies of it. That's how the compounded GLP-1 boom happened — at its peak, compounded versions made up roughly 30% of U.S. GLP-1 supply.

Then the shortages ended. The FDA declared tirzepatide resolved on December 19, 2024 and semaglutide resolved on February 21, 2025 (FDA, 2024–2025). After short wind-down periods, the FDA's enforcement grace for ordinary pharmacies (503A) ran out — for tirzepatide on February 18, 2025 and for semaglutide on April 22, 2025. Compounders sued, and the courts sided with the FDA.

What's still allowed now. A narrow lane remains. A 503A pharmacy can still compound semaglutide or tirzepatide for an individual patient when there's a documented clinical reason the commercial drug won't work — for example, an allergy to an ingredient in the approved product, or a strength that isn't sold commercially. The FDA has been explicit that wanting a lower price is not, by itself, a qualifying reason (FDA).

What's coming. On April 30, 2026, the FDA proposed to permanently remove semaglutide, tirzepatide, and liraglutide from the “503B bulks list” — the list that lets larger facilities compound from bulk ingredients. The agency opened a public comment period running through late June 2026 (FDA, 2026). In plain terms: the FDA is signaling that the era of easy, large-scale GLP-1 compounding is closing.

What this means if you're looking at Embody. Embody's own language says its compounded medicines are dispensed “when clinically appropriate and legally allowed,” and that a clinician decides eligibility during intake. So this isn't a reason to panic — but it is a reason to ask, at intake, what medicine you'd receive and on what basis, and to know the rules here can shift. We re-check this section monthly for exactly that reason.

(We're not your lawyer or your doctor, and this isn't legal or medical advice — it's a plain-language read of public FDA documents so you can ask better questions.)

What is Embody's GLP-1 gum — and how is it different from a shot?

The gum is real, and it's Embody's calling card. The pitch is simple: no needles. For someone who genuinely can't face a weekly shot, that can be the difference between starting and never starting.

A few honest notes so you go in clear-eyed:

• •Both molecules come in gum form. Embody lists a compounded semaglutide gum and a compounded tirzepatide gum on its product pages (Embody, reviewed June 2026). Which one you'd get depends on your prescription. Availability can change, so confirm it's live at checkout.
• •The gum is one piece a day, taken per Embody's instructions.
• •The gum is compounded, like the shots. It is not an FDA-approved product, and it is not the same as FDA-approved oral semaglutide tablets. We make no claim about how well the gum works or how much medicine your body absorbs from it — the FDA hasn't evaluated that, so neither will we. Your clinician can talk through whether a gum or a shot makes more sense for you.
• •Shots have more track record. GLP-1 injections are the format with the most research behind them. A gum trades the needle for a format that's newer and, in compounded form, unstudied by the FDA.

The gum's price (from Embody's Terms): about $149 the first month, then roughly $349/month for semaglutide gum; the tirzepatide gum runs higher. Embody's standalone gum product page lists about $229 for a one-month supply — which doesn't match the Terms, so confirm the real number at checkout.

What does Embody cost after the first month?

This is where a lot of people get surprised, so let's make the real number easy to see. The “jumps up to $299 a month” reaction is common — it's not a scam. It's how Embody's intro pricing works. Your job is to budget for the ongoing rate, not the promo. See also: GLP-1 cost without insurance.

Start Program (intro pricing that rises after month 1)

Source: Embody Terms & Conditions (joinem.co), reviewed June 2026. The 12-month figure is month 1 plus 11 months at the ongoing rate. Confirm live before paying.

Flat Program (lock a steadier monthly rate by committing longer)

Source: Embody Terms & Conditions, reviewed June 2026. Verify before relying on these.

Why the price looks different across Embody's own pages (heads-up)

Here's an original finding worth knowing before you trust any single number, including ours. Embody's pages don't agree with each other (Embody, reviewed June 2026):

• The homepage advertises categories starting around $79/month (GLP-1 injections) and $129/month (GLP-1/GIP injections).
• The Terms list the same injections starting at $99 and $149 the first month.
• The semaglutide gum product page lists about $229 for a one-month supply, which doesn't match the gum pricing in the Terms.

None of that makes Embody dishonest — promo pages, plan types, and product pages get updated at different times. But it does mean the only price that counts is the one on your checkout screen. Screenshot it.

Is Embody legit? Trust signals and red flags to check before you pay

Embody is run by Modern Metabolic Medicine, Inc., with prescriptions written by licensed clinicians and filled by U.S.-based 503A compounding pharmacies. An Embody FAQ says a medical director who is a practicing physician has reviewed its doctor and pharmacy network (Embody, reviewed June 2026). Those are the bones of a legitimate operation.

Independent sentiment is mixed-to-average. Embody's Trustpilot score sat around 3.1 out of 5 across roughly 115 reviews when we checked (Trustpilot, June 2026 — verify current). Happy customers tend to praise the fast onboarding, the shipping, and the gum option. Unhappy ones tend to flag the price jump after month one, recurring billing, and cancellation friction. We use reviews to understand the experience — not as proof a medicine is safe or effective. See full Embody reviews and ratings.

The FDA's own telehealth red flags

The FDA publishes a list of warning signs for buying compounded GLP-1s online. Watch for a company that (FDA, June 2026): claims the compounded drug is the same as an FDA-approved drug; offers prices that seem too good to be true; sends medicine that looks different than expected or arrives warm or damaged; doesn't require screening and a prescription from a licensed doctor; has no licensed doctor available after you get the medicine; or shows a pharmacy name on the label that may be fake. Use that list on any provider — including Embody.

What Embody states vs. what we could confirm

Two things to verify before you trust the checkout

State availability. Embody's own pages don't fully agree. Its marketing says all 50 states, while other Embody pages list exceptions (Mississippi and Louisiana have appeared on that list), and its Terms say service is limited to “certain states” (Embody, reviewed June 2026). Confirm your state during intake before you pay.

The cancellation window. This is the kind of detail that costs people money, so we flag it loudly. Embody's Refund Policy mentions sending a cancellation request at least 72 hours before your billing date. But Embody's Terms say to cancel at least 5 days before the end of your prescription period to avoid the next charge (Embody, reviewed June 2026). Those don't match. Use the stricter 5-day window unless Embody support confirms otherwise in writing — and keep that confirmation.

The 10 questions to ask before you pay

You get to ask for clarity before you hand over a card. Get answers to these:

1. What exact medicine will I receive — semaglutide or tirzepatide?
2. Is it compounded or brand-name?
3. Which pharmacy fills it, and is that pharmacy licensed for my state?
4. What dose do I start on, and how do dose changes work?
5. What's my recurring price after the intro month?
6. Is this a monthly plan, a multi-month plan, or an auto-renewing subscription?
7. Exactly how many days before billing must I cancel?
8. What's the refund policy if I cancel or get disqualified?
9. Who do I contact if I have side effects like nausea or vomiting?
10. Can I get the key terms in writing before my next billing cycle?

If a program can't answer those plainly, that's your red flag — not whether the website looks nice.

What pharmacy does Embody use?

This deserves its own callout because the FDA specifically flags pharmacy-label fraud as a risk with online compounded GLP-1s. Embody describes partnering with multiple U.S.-certified pharmacies (Embody, reviewed June 2026), which is normal — but “a pharmacy” isn't the same as “this named, licensed pharmacy.” Asking for the name is a 30-second step that protects you.

How safe are compounded GLP-1s? What the FDA is tracking

The adverse-event numbers are worth knowing. As of May 31, 2026, the FDA reported 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide (FDA, 2026). The FDA tracks these separately from brand-name products because compounded drugs aren't subject to the same manufacturing controls.

A few safety checkpoints that apply to any compounded GLP-1 program:

• GLP-1 and GLP-1/GIP labels carry a boxed warning for people with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 (a rare inherited condition). Any program should screen for this during intake.
• Dosing errors are a compounding-specific risk. Confirm your starting dose in writing and how titration works.
• If medicine arrives warm, damaged, or looks unexpected, contact the pharmacy immediately — don't use it.
• Common side effects — nausea, vomiting, diarrhea, constipation — are manageable for many people but can be severe. Know who to call.

Also compare the best compounded tirzepatide alternatives if you want to see how providers stack up side-by-side before deciding.

What we actually verified about Embody

Confirmed on Embody's own pages (provider-stated, June 2026):

• Embody markets GLP-1 injection and GLP-1/GIP injection categories.
• Embody's Terms list semaglutide injection, semaglutide gum, tirzepatide injection, and tirzepatide gum.
• Embody has product pages for the compounded semaglutide gum and tirzepatide gum.
• Embody states a clinician decides whether treatment is appropriate.
• Embody states its compounded semaglutide and tirzepatide are not FDA-approved.
• Embody describes recurring subscription billing and cancellation timing.

Confirmed from the FDA (primary sources):

• Compounded GLP-1 drugs are not FDA-approved finished products, and the FDA doesn't review them for safety, effectiveness, or quality before sale.
• The FDA resolved the tirzepatide shortage (Dec 19, 2024) and semaglutide shortage (Feb 21, 2025), ending the shortage-based compounding allowance.
• On April 30, 2026, the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list, with public comment through late June 2026.
• As of May 31, 2026, the FDA reported 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide.

Not verified (confirm at intake/checkout):

• The exact checkout price for your medicine and plan.
• The specific compounding pharmacy's name and credentials.
• Exact state-by-state availability (Embody's pages conflict; Mississippi and Louisiana have appeared as exclusions).
• Whether every gum option is currently live for all eligible patients.
• Whether Embody offers any FDA-approved brand-name checkout path.

By The RX Index editorial team. We reviewed Embody's public homepage, Terms, Refund Policy, medication-safety pages, and product pages, then cross-checked the medical, regulatory, and safety claims against FDA primary sources. We separate verified commercial facts from provider-stated claims and from medical/regulatory facts, and we mark checkout-only items as needing verification. Last verified: June 2026.

FAQ: Embody GLP-1 medications

Sources

• U.S. Food and Drug Administration — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of June 15, 2026; telehealth red flags; adverse-event counts as of May 31, 2026). fda.gov
• U.S. Food and Drug Administration — FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (shortage resolution; 503A/503B enforcement dates). fda.gov
• U.S. Food and Drug Administration — Declaratory Order: Resolution of Semaglutide Injection Product Shortage (decision memo dated Feb 21, 2025). fda.gov
• U.S. Food and Drug Administration — FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (April 30, 2026). fda.gov
• Embody (joinem.co) — homepage; Terms & Conditions; Refund Policy; Medication Safety Information; compounded semaglutide gum and tirzepatide gum product pages. Reviewed June 2026.
• Ro (ro.co) — Weight Loss Program Pricing; oral GLP-1 and semaglutide cost pages. Reviewed June 2026.
• Trustpilot — Embody (joinem.co) rating and reviews (verify current on publish day).
• DailyMed (U.S. National Library of Medicine) — ZEPBOUND (tirzepatide) prescribing information (MTC/MEN 2 boxed warning).
• U.S. Federal Trade Commission — 16 CFR Part 255, Guides Concerning the Use of Endorsements and Testimonials in Advertising.